Literature DB >> 18775425

Blockade of microglial glutamate release protects against ischemic brain injury.

Hideyuki Takeuchi1, Shijie Jin, Hiromi Suzuki, Yukiko Doi, Jianfeng Liang, Jun Kawanokuchi, Tetsuya Mizuno, Makoto Sawada, Akio Suzumura.   

Abstract

Glutamate released by activated microglia induces excito-neurotoxicity and may contribute to neurodegeneration in numerous neurological diseases including ischemia, inflammation, epilepsy, and neurodegenerative diseases. We observed that the gap junction blocker carbenoxolone (CBX) or the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) decreased glutamate release from activated microglia and rescued neuronal death in a dose-dependent manner in vitro. In gerbils, treatment with CBX or DON also prevented the delayed death of hippocampal neurons following transient global ischemia. Thus, blockade of microglial glutamate release may be an effective therapeutic strategy against neurodegeneration after ischemic injury.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18775425     DOI： 10.1016/j.expneurol.2008.08.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


  40 in total

1.  Pannexins in ischemia-induced neurodegeneration.

Authors:  Panagiotis Bargiotas; Antje Krenz; Sheriar G Hormuzdi; Dirk A Ridder; Anne Herb; Waleed Barakat; Silvia Penuela; Jakob von Engelhardt; Hannah Monyer; Markus Schwaninger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-06       Impact factor: 11.205

2.  Induction of autoimmunity to brain antigens by developmental mercury exposure.

Authors:  Yubin Zhang; Donghong Gao; Valerie J Bolivar; David A Lawrence
Journal:  Toxicol Sci       Date:  2010-11-11       Impact factor: 4.849

Review 3.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

4.  Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.

Authors:  L F Agnati; G Leo; S Genedani; L Piron; A Rivera; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

Review 5.  Scutellarin as a Potential Therapeutic Agent for Microglia-Mediated Neuroinflammation in Cerebral Ischemia.

Authors:  Yun Yuan; Ming Fang; Chun-Yun Wu; Eng-Ang Ling
Journal:  Neuromolecular Med       Date:  2016-04-21       Impact factor: 3.843

6.  Protective effect of INI-0602, a gap junction inhibitor, on dopaminergic neurodegeneration of mice with unilateral 6-hydroxydopamine injection.

Authors:  Hiromi Suzuki; Kenji Ono; Makoto Sawada
Journal:  J Neural Transm (Vienna)       Date:  2014-04-18       Impact factor: 3.575

Review 7.  Ionic regulation of cell volume changes and cell death after ischemic stroke.

Authors:  Mingke Song; Shan Ping Yu
Journal:  Transl Stroke Res       Date:  2013-12-07       Impact factor: 6.829

8.  Blockade of gap junction hemichannel protects secondary spinal cord injury from activated microglia-mediated glutamate exitoneurotoxicity.

Authors:  Daisuke Umebayashi; Atsushi Natsume; Hideyuki Takeuchi; Masahito Hara; Yusuke Nishimura; Ryuichi Fukuyama; Naoyuki Sumiyoshi; Toshihiko Wakabayashi
Journal:  J Neurotrauma       Date:  2014-09-23       Impact factor: 5.269

Review 9.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

10.  Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy.

Authors:  Sébastien Talbot; Emna Chahmi; Jenny Pena Dias; Réjean Couture
Journal:  J Neuroinflammation       Date:  2010-06-29       Impact factor: 8.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.